A recent study demonstrated tumor necrosis factor receptor-associated factor 6 (TRAF6) as a key regulatory factor for Wnt3a-induced regulation of β-catenin and subsequent activation of Wnt3a target genes implicated in prostate cancer progression, suggesting TRAF6 as an important novel target for inhibiting cancer [189]. This evidence concerns the gene WNT3A and prostate carcinoma.